Switzerland’s handling of its COVID-19 vaccine procurement contracts has come under intense scrutiny, with political figures and advocacy groups accusing federal authorities of misleading the public and failing to secure adequate manufacturer accountability. The controversy centers on agreements with Moderna and Novavax, which critics claim contain no binding obligations for the companies to deliver effective or safe vaccines, whereas placing all liability on the state and taxpayers.
The allegations gained prominence in April 2026 when the Swiss People’s Party (SVP) National Council member Rémy Wyssmann, similarly serving as cantonal president of SVP Solothurn, brought forward motions during a special parliamentary session demanding greater transparency and stricter liability rules for federal officials involved in the procurement process. Wyssmann, who played a key role in securing the partial declassification of the contracts, asserted that the Federal Council had presented false information regarding the terms of the agreements.
These developments follow sustained pressure from the Aktionbündnis freie Schweiz (Free Switzerland Action Alliance), which commissioned a legal analysis of the now-publicly available contracts with Moderna and Novavax. According to the group’s findings presented in Bern in mid-April 2026, despite the stated purpose of protecting public health during the pandemic, none of the agreements include any enforceable commitments from the manufacturers concerning vaccine efficacy or safety. Instead, the analysis concluded that liability risks are borne exclusively by the Swiss government and, by extension, taxpayers.
The alliance described the results of its legal review as “shocking,” arguing that the Federal Office of Public Health (FOPH/BAG) engaged in what it termed “dark chamber politics” by maintaining heavy redactions in the contracts for an extended period, only releasing partial details after legal and political pressure. Critics contend that this lack of transparency undermines democratic oversight and violates principles of public procurement law, which require clarity on deliverables, warranties, and liability allocation.
In response to the allegations, Wyssmann announced plans to introduce formal parliamentary motions in the upcoming special session of the Federal Assembly, calling for accountability measures against senior federal officials responsible for the vaccine procurement process. He emphasized the need to determine whether the Federal Council violated mandatory procurement guidelines and whether it unlawfully withheld essential contract details from parliament.
The debate has reignited broader discussions about pandemic-era decision-making, governmental transparency, and the balance between expedient public health action and contractual safeguards. As of late April 2026, the contracts remain subject to ongoing review, with no official statement from the Federal Council or FOPH directly addressing the specific claims of missing efficacy or safety obligations in the Moderna and Novavax agreements.
For ongoing updates on this developing story, including any future parliamentary proceedings or official responses, readers are encouraged to consult official channels such as the Swiss Federal Assembly website and the Federal Office of Public Health publications.
Share your thoughts on this important issue in the comments below, and help spread awareness by sharing this article with others interested in government accountability and public health policy.